Asher Biotherapeutics AB248 & Rilvegostomig in NSCLC: Phase 1b/2 Study Announced
Asher Biotherapeutics and AstraZeneca have partnered to evaluate etakafusp alfa (AB248), Asher Bio’s CD8+ T cell-targeted IL-2 immunotherapy, in...
Micron Secures $43M for Measles, Rubella & Needle-Free Infant Vaccines
Micron Biomedical received a $7.5 million grant from the Bill & Melinda Gates Foundation, bringing total funding from the...
Solid Biosciences Announces FDA IND Clearance for First-in-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences has received FDA clearance for its Investigational New Drug (IND) application for SGT-212, a gene therapy designed...
Sana Biotechnology Shows Positive Results in Type 1 Diabetes Study
Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study,...
Sight Sciences Study Shows OMNI’s Effectiveness in Glaucoma Management
A 36-month study using data from the American Academy of Ophthalmology IRIS® Registry demonstrated that Sight Sciences’ OMNI® Surgical...
Immix BioPharma NXC-201 CAR-T Trial in US for AL Amyloidosis Sees Accelerated Enrollment
Immix Biopharma has completed the safety run-in portion of its U.S. Phase 1b NEXICART-2 study for NXC-201, a CAR-T...
Cyclarity Therapeutics Gets FDA Nod for First Human Clinical Trial
Cyclarity Therapeutics has received regulatory approval to commence its first-in-human clinical trial for UDP-003 at CMAX in Australia, partnered...
Biomea Fusion Reveals Promising Preclinical Data on Icovamenib Combination
Biomea Fusion announced positive preclinical data for icovamenib combined with semaglutide, a GLP-1 receptor agonist, in treating type 2...
Grove Secures $4.9M for Agentic AI Clinical Trials
Grove AI, a clinical trial management company, secured $4.9 million in seed funding led by A•, with participation from...
How Technology Can Address Upcoming Big Pharma Financial Crunch
In this interview, we speak with Jim Corrigan, CEO of YPrime, about the future of clinical trial technologies. The...